HUP0402270A3 - [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them - Google Patents
[1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing themInfo
- Publication number
- HUP0402270A3 HUP0402270A3 HU0402270A HUP0402270A HUP0402270A3 HU P0402270 A3 HUP0402270 A3 HU P0402270A3 HU 0402270 A HU0402270 A HU 0402270A HU P0402270 A HUP0402270 A HU P0402270A HU P0402270 A3 HUP0402270 A3 HU P0402270A3
- Authority
- HU
- Hungary
- Prior art keywords
- triazolo
- pyrimidin
- adenosine
- amines
- pharmaceutical compositions
- Prior art date
Links
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title 1
- WLMIXIOSYFFELW-UHFFFAOYSA-N [1,2,4]triazolo[1,5-c]pyrimidin-5-amine Chemical class NC1=NC=CC2=NC=NN12 WLMIXIOSYFFELW-UHFFFAOYSA-N 0.000 title 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33429301P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/038134 WO2003048164A2 (en) | 2001-11-30 | 2002-11-26 | Adenosine a2a receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0402270A2 HUP0402270A2 (hu) | 2005-02-28 |
| HUP0402270A3 true HUP0402270A3 (en) | 2008-09-29 |
Family
ID=23306533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0402270A HUP0402270A3 (en) | 2001-11-30 | 2002-11-26 | [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7041666B2 (hu) |
| EP (1) | EP1453835B1 (hu) |
| JP (2) | JP4284181B2 (hu) |
| KR (1) | KR20050044607A (hu) |
| CN (1) | CN1596258A (hu) |
| AR (1) | AR038366A1 (hu) |
| AT (1) | ATE317844T1 (hu) |
| AU (1) | AU2002346572A1 (hu) |
| CA (1) | CA2468681C (hu) |
| DE (1) | DE60209251T2 (hu) |
| ES (1) | ES2258164T3 (hu) |
| HK (1) | HK1064100A1 (hu) |
| HU (1) | HUP0402270A3 (hu) |
| IL (1) | IL161572A0 (hu) |
| MX (1) | MXPA04005156A (hu) |
| PE (1) | PE20030739A1 (hu) |
| TW (1) | TW200300686A (hu) |
| WO (1) | WO2003048164A2 (hu) |
| ZA (1) | ZA200404160B (hu) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1544200A1 (en) * | 2002-09-24 | 2005-06-22 | Kyowa Hakko Kogyo Co., Ltd. | 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE |
| NZ540493A (en) | 2002-12-19 | 2008-04-30 | Schering Corp | Uses of adenosine A2a receptor antagonists |
| US20060106040A1 (en) | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| WO2004092172A2 (en) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists |
| JP4800216B2 (ja) * | 2003-10-24 | 2011-10-26 | エグゼリクシス， インコーポレイテッド | ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法 |
| AR050926A1 (es) * | 2004-09-03 | 2006-12-06 | Astrazeneca Ab | Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac) |
| JPWO2006129626A1 (ja) * | 2005-05-30 | 2009-01-08 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法 |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| KR20100022080A (ko) * | 2007-05-24 | 2010-02-26 | 미쓰비시 타나베 파마 코퍼레이션 | 뇌경색 치료제 |
| JP2010531364A (ja) * | 2007-06-25 | 2010-09-24 | ニューロジェン・コーポレーション | ピペラジニルオキソアルキルテトラヒドロ−β−カルボリンおよび関連類似体 |
| US20100093764A1 (en) * | 2008-10-13 | 2010-04-15 | Devraj Chakravarty | AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| US20100093756A1 (en) * | 2008-10-13 | 2010-04-15 | Berbay J Kent | HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| RU2472257C1 (ru) | 2008-11-25 | 2013-01-10 | Ниссан Мотор Ко., Лтд. | Электропроводный узел и топливный элемент с полимерным электролитом с его использованием |
| EP2424840B1 (en) * | 2009-04-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Cxcr3 receptor antagonists |
| US8952004B2 (en) | 2010-01-07 | 2015-02-10 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
| CA2812378C (en) * | 2010-09-24 | 2016-11-29 | Advinus Therapeutics Limited | Fused tricyclic compounds as adenosine receptor antagonist |
| WO2012127472A1 (en) * | 2011-03-22 | 2012-09-27 | Mapi Pharma Ltd. | Process and intermediates for the preparation of preladenant and related compounds |
| PL3611174T3 (pl) * | 2017-04-07 | 2022-08-08 | Medshine Discovery Inc. | Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a |
| JP7474709B2 (ja) * | 2018-02-27 | 2024-04-25 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン |
| JP7406691B2 (ja) * | 2018-04-28 | 2023-12-28 | イノレイク・バイオファーマ（ハンジョウ）・カンパニー・リミテッド | トリアゾロピリミジン系化合物の結晶形、塩のタイプおよびその調製方法 |
| MA52940A (fr) * | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| AU2019297361B2 (en) | 2018-07-05 | 2024-06-27 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| TWI820209B (zh) * | 2018-09-12 | 2023-11-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | 三唑并－嘧啶化合物及其用途 |
| MA55142A (fr) | 2018-11-20 | 2022-02-23 | Merck Sharp & Dohme | Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
| WO2020106560A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| AU2019385905B2 (en) | 2018-11-30 | 2023-01-12 | Merck Sharp & Dohme Llc | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
| AU2019401649A1 (en) | 2018-12-20 | 2021-07-08 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
| WO2020128036A1 (en) * | 2018-12-21 | 2020-06-25 | Ryvu Therapeutics S.A. | Modulators of the adenosine a2a receptor |
| TWI829857B (zh) * | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| ES2165393T3 (es) | 1993-07-27 | 2002-03-16 | Kyowa Hakko Kogyo Kk | Remedio contra la enfermedad de parkinson. |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| CA2284737C (en) | 1997-03-24 | 2007-03-13 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]triazolo[1,5-c]pyrimidine derivatives |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| IL142128A0 (en) | 1998-09-22 | 2002-03-10 | Kyowa Hakko Kogyo Kk | [1,2,4] triazolo [1,5-c] pyrimidine derivatives |
| US6630475B2 (en) | 2000-05-26 | 2003-10-07 | Schering Corporation | Adenosine A2a receptor antagonists |
| WO2002079204A1 (fr) * | 2001-03-28 | 2002-10-10 | Kyowa Hakko Kogyo Co., Ltd. | Derive 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine |
| DE60219196T2 (de) | 2001-11-30 | 2008-01-03 | Schering Corp. | BICYCLISCHE [1,2,4]-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN |
-
2002
- 2002-11-25 AR ARP020104528A patent/AR038366A1/es unknown
- 2002-11-25 PE PE2002001128A patent/PE20030739A1/es not_active Application Discontinuation
- 2002-11-25 TW TW091134178A patent/TW200300686A/zh unknown
- 2002-11-26 WO PCT/US2002/038134 patent/WO2003048164A2/en active IP Right Grant
- 2002-11-26 US US10/304,504 patent/US7041666B2/en not_active Expired - Lifetime
- 2002-11-26 EP EP02784641A patent/EP1453835B1/en not_active Expired - Lifetime
- 2002-11-26 ES ES02784641T patent/ES2258164T3/es not_active Expired - Lifetime
- 2002-11-26 IL IL16157202A patent/IL161572A0/xx unknown
- 2002-11-26 DE DE60209251T patent/DE60209251T2/de not_active Expired - Lifetime
- 2002-11-26 HU HU0402270A patent/HUP0402270A3/hu unknown
- 2002-11-26 AU AU2002346572A patent/AU2002346572A1/en not_active Abandoned
- 2002-11-26 KR KR1020047008031A patent/KR20050044607A/ko not_active Application Discontinuation
- 2002-11-26 CA CA2468681A patent/CA2468681C/en not_active Expired - Fee Related
- 2002-11-26 CN CNA028239229A patent/CN1596258A/zh active Pending
- 2002-11-26 MX MXPA04005156A patent/MXPA04005156A/es active IP Right Grant
- 2002-11-26 JP JP2003549354A patent/JP4284181B2/ja not_active Expired - Fee Related
- 2002-11-26 AT AT02784641T patent/ATE317844T1/de not_active IP Right Cessation
-
2004
- 2004-05-27 ZA ZA200404160A patent/ZA200404160B/en unknown
- 2004-09-11 HK HK04106913A patent/HK1064100A1/xx not_active IP Right Cessation
-
2008
- 2008-06-04 JP JP2008147394A patent/JP2008303217A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003048164A2 (en) | 2003-06-12 |
| AR038366A1 (es) | 2005-01-12 |
| PE20030739A1 (es) | 2003-08-28 |
| CN1596258A (zh) | 2005-03-16 |
| JP4284181B2 (ja) | 2009-06-24 |
| WO2003048164A3 (en) | 2003-10-16 |
| ES2258164T3 (es) | 2006-08-16 |
| IL161572A0 (en) | 2004-09-27 |
| JP2005511698A (ja) | 2005-04-28 |
| EP1453835A2 (en) | 2004-09-08 |
| JP2008303217A (ja) | 2008-12-18 |
| HK1064100A1 (en) | 2005-01-21 |
| CA2468681A1 (en) | 2003-06-12 |
| US7041666B2 (en) | 2006-05-09 |
| DE60209251T2 (de) | 2006-11-09 |
| MXPA04005156A (es) | 2004-08-11 |
| KR20050044607A (ko) | 2005-05-12 |
| ZA200404160B (en) | 2005-04-08 |
| EP1453835B1 (en) | 2006-02-15 |
| CA2468681C (en) | 2011-01-25 |
| US20030212080A1 (en) | 2003-11-13 |
| TW200300686A (en) | 2003-06-16 |
| HUP0402270A2 (hu) | 2005-02-28 |
| AU2002346572A1 (en) | 2003-06-17 |
| DE60209251D1 (de) | 2006-04-20 |
| ATE317844T1 (de) | 2006-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0402270A3 (en) | [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them | |
| HUP0401777A3 (en) | 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds | |
| HUP0600239A2 (en) | 5-amino-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, process for their preparation, their use as adenosine a2a receptor antagonists and pharmaceutical compositions containing them | |
| HUP0401047A3 (en) | Triazolo[4,5-d]pyrimidine derivatives, their use as purinergic receptor antagonist and pharmaceutical compositions containing same | |
| HUP0402324A3 (en) | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them | |
| HUP0402018A3 (en) | 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them | |
| HUP0301114A3 (en) | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them | |
| HUP0401925A3 (en) | A2b adenosine receptor antagonists | |
| IL155712A0 (en) | Aminothiazoles and their use as adenosine receptor antagonists | |
| HUP0401301A3 (en) | Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0401987A3 (en) | Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments | |
| IL191960A (en) | History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them | |
| HUP0202810A3 (en) | Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands, process for their preparation and pharmaceutical compositions containing them | |
| HUP0203503A3 (en) | Pyrrolo[2,3-d]pirimidine compounds, pharmaceutical compositions containing them and their use | |
| HUP0400784A3 (en) | Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them | |
| HUP0200308A2 (en) | Quinolinecarboxamides as antiviral agents, pharmaceutical compositions containing them and their use | |
| HK1043591B (zh) | 取代的2-芳基-3-(雜芳基)-咪唑並[1，2-a]嘧啶類化合物以及相關的藥物組合物和方法 | |
| HUP0401718A3 (en) | Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them | |
| HUP0500328A3 (en) | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them | |
| IL156536A0 (en) | Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same | |
| SI1622912T1 (sl) | 2-alkinil- in 2-alkenil-pirazolo-(4,3-E)-1,2,4-triazolo-(1,5-C)-pirimidin adenozinski A2a receptorski antagonisti | |
| HUP0201649A2 (en) | Purine derivatives, preparation method and pharmaceutical compositions containing same | |
| HUP0105054A3 (en) | Imidazo[4,5-c]-pyridine-4-on-derivatives, pharmaceutical compositions containing them and process for their preparation | |
| IL160715A0 (en) | Pharmaceutical compositions containing an a1 adenosine receptor antagonist | |
| HUP0301587A3 (en) | 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect, pharmaceutical compositions containing them and processes for their preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |